Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

NCT03232112 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a medication called GLP-1 can help reduce heavy drinking in adults who have alcohol dependence.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 152 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2017-08 · est. completion 2020-10

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT03232112 ↗

Description as written by the study sponsor.

The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs. placebo on alcohol intake in patients with a diagnosis of alcohol dependence.

Treatments tested

Exenatide 2 MG Injection also known as Bydureon Pen, 2 Mg, Extended Release Drug

Subcutaneous injection once-weekly
BD PosiFlush (saline) also known as Saline Drug

Subcutaneous injection once-weekly

Main thing measured	Heavy drinking days
Sponsor	Anders Fink-Jensen, MD, DMSci
Conditions studied	Alcohol Dependence, in Remission, Addiction, Alcohol
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03232112 ↗